753 related articles for article (PubMed ID: 30678757)
1. Long-Term Follow-Up After Closure of Patent Foramen Ovale in Patients With Cryptogenic Embolism.
Wintzer-Wehekind J; Alperi A; Houde C; Côté JM; Asmarats L; Côté M; Rodés-Cabau J
J Am Coll Cardiol; 2019 Jan; 73(3):278-287. PubMed ID: 30678757
[TBL] [Abstract][Full Text] [Related]
2. Impact of Discontinuation of Antithrombotic Therapy Following Closure of Patent Foramen Ovale in Patients With Cryptogenic Embolism.
Wintzer-Wehekind J; Alperi A; Houde C; Côté JM; Guimaraes LFC; Côté M; Rodés-Cabau J
Am J Cardiol; 2019 May; 123(9):1538-1545. PubMed ID: 30792001
[TBL] [Abstract][Full Text] [Related]
3. Predictors of recurrent events in patients with cryptogenic stroke and patent foramen ovale within the CLOSURE I (Evaluation of the STARFlex Septal Closure System in Patients With a Stroke and/or Transient Ischemic Attack Due to Presumed Paradoxical Embolism Through a Patent Foramen Ovale) trial.
Elmariah S; Furlan AJ; Reisman M; Burke D; Vardi M; Wimmer NJ; Ling S; Chen X; Kent DM; Massaro J; Mauri L;
JACC Cardiovasc Interv; 2014 Aug; 7(8):913-20. PubMed ID: 25147037
[TBL] [Abstract][Full Text] [Related]
4. Long-term follow-up after PFO device closure: Outcomes and Complications in a Single-center Experience.
Taggart NW; Reeder GS; Lennon RJ; Slusser JP; Freund MA; Cabalka AK; Cetta F; Hagler DJ
Catheter Cardiovasc Interv; 2017 Jan; 89(1):124-133. PubMed ID: 27027873
[TBL] [Abstract][Full Text] [Related]
5. Risk of recurrent cerebrovascular events in patients with cryptogenic stroke or transient ischemic attack and patent foramen ovale: the FORI (Foramen Ovale Registro Italiano) study.
Paciaroni M; Agnelli G; Bertolini A; Pezzini A; Padovani A; Caso V; Venti M; Alberti A; Palmiero RA; Cerrato P; Silvestrelli G; Lanari A; Previdi P; Corea F; Balducci A; Ferri R; Falcinelli F; Filippucci E; Chiocchi P; Grandi FC; Ferigo L; Musolino R; Bersano A; Ghione I; Sacco S; Carolei A; Baldi A; Ageno W;
Cerebrovasc Dis; 2011; 31(2):109-16. PubMed ID: 21088390
[TBL] [Abstract][Full Text] [Related]
6. Long-term experience and outcomes with transcatheter closure of patent foramen ovale.
Inglessis I; Elmariah S; Rengifo-Moreno PA; Margey R; O'Callaghan C; Cruz-Gonzalez I; Baron S; Mehrotra P; Tan TC; Hung J; Demirjian ZN; Buonanno FS; Ning M; Silverman SB; Cubeddu RJ; Pomerantsev E; Schainfeld RM; Dec GW; Palacios IF
JACC Cardiovasc Interv; 2013 Nov; 6(11):1176-83. PubMed ID: 24262618
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Outcomes after Device Closure and Medication Alone in Patients with Patent Foramen Ovale and Cryptogenic Stroke in Korean Population.
Moon J; Kang WC; Kim S; Oh PC; Park YM; Chung WJ; Choi DY; Lee JY; Lee YB; Hwang HY; Ahn T
Yonsei Med J; 2016 May; 57(3):621-5. PubMed ID: 26996560
[TBL] [Abstract][Full Text] [Related]
8. Interventional closure of patent foramen ovale with Nit-occlud® device in prevention of recurrent neurologic events-Long-term results.
Araszkiewicz A; Sławek S; Trojnarska O; Lesiak M; Grygier M
Catheter Cardiovasc Interv; 2018 Jul; 92(1):159-164. PubMed ID: 29068141
[TBL] [Abstract][Full Text] [Related]
9. Closure versus medical therapy for preventing recurrent stroke in patients with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack.
Li J; Liu J; Liu M; Zhang S; Hao Z; Zhang J; Zhang C
Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD009938. PubMed ID: 26346232
[TBL] [Abstract][Full Text] [Related]
10. Sex Differences in Patients With Cryptogenic Cerebrovascular Events Undergoing Transcatheter Closure of Patent Foramen Ovale.
Farjat-Pasos JI; Guedeney P; Houde C; Alperi A; Robichaud M; Côté M; Montalescot G; Rodés-Cabau J
J Am Heart Assoc; 2023 Oct; 12(19):e030359. PubMed ID: 37776218
[TBL] [Abstract][Full Text] [Related]
11. Percutaneous closure of patent foramen ovale in cryptogenic embolism.
Meier B; Kalesan B; Mattle HP; Khattab AA; Hildick-Smith D; Dudek D; Andersen G; Ibrahim R; Schuler G; Walton AS; Wahl A; Windecker S; Jüni P;
N Engl J Med; 2013 Mar; 368(12):1083-91. PubMed ID: 23514285
[TBL] [Abstract][Full Text] [Related]
12. Ten years of experience with closure of persistent foramen ovale: patient characteristics and outcomes.
Lehmann R; Fichtlscherer S; Baldauf H; Schächinger V; Auch-Schwelck W; Zeiher AM; Teupe C
J Cardiol; 2014 Aug; 64(2):113-6. PubMed ID: 24480741
[TBL] [Abstract][Full Text] [Related]
13. Transcatheter Closure of Patent Foramen Ovale in Older Patients With Cryptogenic Thromboembolic Events.
Alperi A; Guedeney P; Horlick E; Nombela-Franco L; Freixa X; Pascual I; Mesnier J; Houde C; Abrahamyan L; Montalescot G; Rodés-Cabau J
Circ Cardiovasc Interv; 2022 Jul; 15(7):e011652. PubMed ID: 35735021
[TBL] [Abstract][Full Text] [Related]
14. Long-term propensity score-matched comparison of percutaneous closure of patent foramen ovale with medical treatment after paradoxical embolism.
Wahl A; Jüni P; Mono ML; Kalesan B; Praz F; Geister L; Räber L; Nedeltchev K; Mattle HP; Windecker S; Meier B
Circulation; 2012 Feb; 125(6):803-12. PubMed ID: 22238228
[TBL] [Abstract][Full Text] [Related]
15. Long-Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke.
Saver JL; Carroll JD; Thaler DE; Smalling RW; MacDonald LA; Marks DS; Tirschwell DL;
N Engl J Med; 2017 Sep; 377(11):1022-1032. PubMed ID: 28902590
[TBL] [Abstract][Full Text] [Related]
16. Multidisciplinary assessment of PFO with substantial right-to-left shunting and medium-term follow-up after PFO device closure: A single-center experience.
He L; Cheng GS; Du YJ; Zhang YS
J Interv Cardiol; 2017 Aug; 30(4):362-367. PubMed ID: 28568903
[TBL] [Abstract][Full Text] [Related]
17. Transcatheter closure of patent foramen ovale in patients older than 60 years of age with cryptogenic embolism.
Wintzer-Wehekind J; Alperi A; Houde C; Côté JM; Del Val D; Côté M; Rodés-Cabau J
Rev Esp Cardiol (Engl Ed); 2020 Mar; 73(3):219-224. PubMed ID: 31585849
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcomes of patent foramen ovale closure or medical therapy after cryptogenic stroke: A meta-analysis of randomized trials.
Abdelaziz HK; Saad M; Abuomara HZ; Nairooz R; Pothineni NVK; Madmani ME; Roberts DH; Mahmud E
Catheter Cardiovasc Interv; 2018 Jul; 92(1):176-186. PubMed ID: 29726616
[TBL] [Abstract][Full Text] [Related]
19. Post-Market Clinical Follow-Up With the Patent Foramen Ovale Closure Device IrisFIT (Lifetech) in Patients With Stroke, Transient Ischemic Attack, or Other Thromboembolic Events.
Sievert K; Yu J; Bertog S; Hornung M; von Bardeleben RS; Gafoor S; Reinartz M; Matic P; Hofmann I; Grunwald I; Schnelle N; Sievert H
Cardiovasc Revasc Med; 2021 Sep; 30():72-75. PubMed ID: 33097460
[TBL] [Abstract][Full Text] [Related]
20. Recurrent events after percutaneous closure of patent foramen ovale.
Wallenborn J; Bertog SC; Franke J; Steinberg DH; Majunke N; Wilson N; Wunderlich N; Sievert H
Catheter Cardiovasc Interv; 2013 Oct; 82(4):541-6. PubMed ID: 22707325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
